Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
Summary not available.
Summary not available.
Summary not available.
LeMaitre Vascular (LMAT) has secured an exclusive distribution agreement for Aziyo Biologics' cardiovascular patches in the U.S. for three years, with an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year. The patches, including ProxiCor®, VasCure®, and Tyke®, utilize an extracellular matrix aimed at reducing inflammation and promoting healthy tissue formation. Aziyo reported $6.8 million in sales from these patches in 2022. LeMaitre anticipates a 50% gross margin from patch sales. President David Roberts expressed enthusiasm about enhancing the company's product offerings for vascular and cardiac surgeons. Further financial implications of this agreement will be detailed in LeMaitre’s Q1 2023 earnings call on May 2, 2023.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q1 2023 financial results on May 2, 2023, after market closure. A conference call is scheduled for 5:00 PM ET on the same day to discuss the results and outlook for the company. Interested parties can register for the call here. The company provides devices and services for treating peripheral vascular disease, impacting over 200 million people globally, and focuses on the needs of vascular surgeons.
LeMaitre Vascular (Nasdaq: LMAT) announced the acquisition of its Thai distributor, Prompt Serve, for $688,000. In 2022, Prompt Serve sold approximately $1.5 million of LeMaitre products to Thai hospitals. This acquisition will enable LeMaitre to establish a direct sales presence in Thailand, marking its 29th direct-to-hospital country and 8th in the APAC region. Jacob Petersen, VP of Asia-Pacific, noted this move is part of their ongoing expansion, aiming for over 90% of operations to be direct in the APAC market. Further financial guidance regarding the impact on 2023 revenue and earnings will be provided during the Q1 earnings call.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in four investor conferences in March 2023. Key events include the 35th Annual Roth Conference on March 13, featuring President David Roberts in a fireside chat at 12:30 PM PT. On March 15, the Oppenheimer 33rd Annual Healthcare Conference will feature CFO JJ Pellegrino at 8:40 AM ET, followed by Roberts presenting at the Barclays Global Healthcare Conference at 2:35 PM ET. Finally, on March 22, Roberts will present at the KeyBanc Life Sciences & MedTech Investor Forum at 3:00 PM ET. LeMaitre provides innovative devices for peripheral vascular disease, serving a global market of over 200 million patients.
LeMaitre (Nasdaq:LMAT) reported Q4 2022 results showing a 4% increase in sales to $41.0 million, with organic sales growth of 8%. Operating income fell 16% to $7.0 million, while net income declined 9% to $5.6 million, resulting in earnings per share of $0.25. The gross margin decreased to 63.6% due to a strong dollar. The company announced a quarterly dividend of $0.14/share (+12%) and provided optimistic guidance for Q1 2023, expecting sales of $42.6 million to $45.0 million (+11%). Full-year sales guidance is projected at $174.3 million to $178.3 million (+9%). A stock repurchase program of $25 million was also authorized.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will announce its fourth quarter 2022 financial results on February 23, 2023, after market close. Following the release, a conference call is scheduled for 5:00 PM ET to discuss the results, business highlights, and outlook for the company. LeMaitre specializes in devices, implants, and services for treating peripheral vascular diseases affecting over 200 million globally. The company's portfolio addresses the needs of vascular surgeons, with a focus on disposable and implantable vascular devices.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two significant investor conferences. David Roberts, President, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 3:10 PM ET in New York City. Additionally, he will present at the Sidoti Small-Cap Virtual Conference on December 8, 2022, at 1:15 PM ET. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million individuals globally.